Income Statement

v3.10.0.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2018
Dec. 31, 2017
Condensed Consolidated Statements Of Operations        
PRODUCT REVENUE, NET $ 413,109 $ 62,977 $ 472,509 $ 179,534
COST OF REVENUE, PRODUCT 379,582 50,370 439,740 140,706
GROSS MARGIN 33,527 12,607 32,769 38,828
EXPENSES        
Sales and marketing (including stock based compensation of nil, $47,111, $210,000 and $47,111, respectively) 100,730 165,315 556,167 229,674
General and administrative (including stock based compensation of $1,133,534, $13,889, $1,271,959 and $26,389, respectively) 1,317,469 133,977 1,712,667 358,193
Depreciation and Amortization 292 56,172 877 168,428
TOTAL OPERATING EXPENSES 1,418,491 355,464 2,269,711 756,295
OPERATING LOSS (1,384,964) (342,857) (2,236,942) (717,467)
Other Income (Expense)        
Unrealized gain on equity investments 404,763
Interest Expense (506,579) (574,880)
Total other income, net (506,579) (170,117)
NET LOSS (1,891,543) (342,856) (2,407,059) (717,467)
Less: Net loss (income) attributable to non controlling interest (234) 7,131 9,358 5,997
NET LOSS ATTRIBUTABLE TO APPLIED BIOSCIENCES CORP. $ (1,891,777) $ (335,726) $ (2,397,701) $ (711,470)
LOSS PER COMMON SHARE $ (0.16) $ (0.02) $ (0.22) $ (0.05)
WEIGHTED AVERAGE SHARES OUTSTANDING        
Basic and diluted 11,797,297 15,595,100 11,150,168 15,458,775

Source